Prostate cancer is the most common cancer in men in many parts of the world, with more than 60,000 cases diagnosed each year in the United Kingdom alone. Caught early, it is treatable. But the treatments most commonly offered — surgery to remove the prostate gland, or radiotherapy to the whole organ — carry significant risks of long-term side effects. Urinary incontinence and erectile dysfunction are common outcomes, affecting quality of life for years after treatment ends.
Now, a major clinical trial has found that a more targeted approach works just as well at controlling cancer — and cuts the risk of those side effects roughly in half.
The study, one of the largest and longest of its kind, followed more than 3,500 men over 10 years. It found that focal therapy — a technique that targets and destroys only the cancerous portion of the prostate, leaving healthy tissue intact — was as effective at controlling cancer as surgery or radiotherapy over the full decade. Patients who received focal therapy were significantly less likely to develop urinary incontinence or loss of sexual function.
"This is the largest and longest running study demonstrating that focal therapy delivers excellent long-term cancer control across a broad range of patients," said Professor Hashim Ahmed, chair of urology at Imperial College London, who led the research. "It makes a compelling case for more centres to offer this treatment."
Focal therapy works using a range of energy-delivery methods — including high-intensity focused ultrasound (HIFU), cryotherapy using extreme cold, and laser ablation — to destroy cancerous cells. Unlike whole-gland treatments, which treat the entire prostate and affect surrounding nerves and muscles, focal therapy is precisely mapped to the tumor site using high-resolution imaging. This precision is what gives it its side-effect advantage: the nerves responsible for bladder control and sexual function are largely spared.
The trial's 10-year timeframe is particularly meaningful. Prostate cancer treatments are often evaluated over five years, but the disease can return after that window. Demonstrating durable effectiveness over a decade strengthens the evidence considerably — and gives patients and clinicians confidence that short-term results are not masking problems that emerge later.
Until now, focal therapy has been offered at only a small number of specialist centers. Many men are unaware it exists, and it has often been framed as experimental rather than proven. The new data could change that. The UK's National Health Service has signaled interest in expanding access, and the study results coincide with government commitments to fund additional treatment capacity.
"A man diagnosed with prostate cancer today has a much better chance of preserving his quality of life than he did even ten years ago," said Professor Ahmed. "The key is matching the right treatment to the right patient — and we now have much stronger evidence for how to do that."
Not all prostate cancers are suitable for focal therapy. Higher-risk tumors that have spread beyond one area of the gland may still require whole-gland treatment. But for the substantial proportion of men whose cancer is localized and clearly defined on imaging, focal therapy now represents a compelling, evidence-backed option.
The study has also helped identify which patients benefit most, giving clinicians clearer guidance on patient selection. That precision matters profoundly in prostate cancer, where treatment decisions affect a patient's daily life for decades.
For the men who participated in the trial — some of whom gave a decade of follow-up to make this evidence possible — the results are both a personal vindication and a gift to future patients. Because of their participation, tens of thousands of men diagnosed with prostate cancer in the years ahead will have a better-informed conversation with their doctors about preserving not just their lives, but their quality of life.
